This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses (compared to complete primary vaccination with no booster) against hospitalisation due to COVID-19 and COVID-19-related death in resident populations ≥50 years of age living in the community.
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses, against hospitalisation due to COVID-19 and COVID-19 related deaths in resident populations ≥50 years of age, living in the community.
The epidemiological situation of SARS-CoV-2 in humans and animals is continually evolving. To date, animal species known to transmit SARS-CoV-2 are American mink, raccoon dog, cat, ferret, hamster, house mouse, Egyptian fruit bat, deer mouse and white-tailed deer. Among farmed animals, American mink have the highest likelihood to become infected from humans or animals and further transmit SARS-CoV-2.
According to the current ECDC assessment, there is moderate probability of XBB.1.5 becoming dominant in the EU/EEA and causing a substantial increase in the number of COVID-19 cases within the next one to two months.
In recent weeks, respiratory syncytial virus (RSV) circulation in the EU/EEA has intensified, with increasing transmission rates in all population groups and an earlier-than-usual start of the season. Several EU/EEA countries are experiencing high RSV circulation and the number of severe acute respiratory infections (SARI) due to RSV is increasing. At this time of the year RSV infections are not unusual, however this year there is more RSV activity and it began earlier than in pre-COVID-19 seasons.
The primary aim of this systematic review and meta-analysis was to estimate the prevalence of symptoms of post COVID-19 condition, stratified by recruitment setting (community, hospital and Intensive Care Unit (ICU)) as a proxy for disease severity.
The SARS-CoV-2 Omicron variant of concern (VOC) is rapidly replacing SARS-CoV-2 Delta in most European Union/European Economic Area (EU/EEA) countries, and is broadly following a west-to-east progression.
The risk to public health posed by the spread of the Omicron VOC in the context of ongoing Delta VOC transmission in the EU/EEA is assessed in this update.
The number of countries reporting SARS-CoV-2 Omicron variant of concern (VOC) cases continues to increase globally, with a total of 352 confirmed cases reported by 27 countries as of 16.00 on 1 December 2021, including 70 confirmed cases reported by 13 European Union and European Economic Area (EU/EEA) countries.